Patents by Inventor Marco Biamonte
Marco Biamonte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8017628Abstract: Sulfonyl hydrazide compounds according to formula I geometrical isomers thereof, optically active enantiomers thereof, diastereomers thereof, racemates thereof, and/or pharmaceutically acceptable salts thereof are useful in method for treating a neuronal disorder, an autoimmune disease, a cardiovascular disease, or cancer in a patient in need of such treatment.Type: GrantFiled: July 14, 2008Date of Patent: September 13, 2011Assignee: Merck Serono S.A.Inventors: Stephen Arkinstall, Serge Halazy, Dennis Church, Montserrat Camps, Thomas Rueckle, Jean-Pierre Gotteland, Marco Biamonte
-
Patent number: 8012995Abstract: The present invention is related to sulfonamide derivatives of formula (I0 notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation.Type: GrantFiled: September 28, 2000Date of Patent: September 6, 2011Assignee: Merck Serono SAInventors: Stephen Arkinstall, Serge Halazy, Dennis Church, Montserrat Camps, Thomas Rueckle, Jean Pierre Gotteland, Marco Biamonte
-
Patent number: 8008341Abstract: The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3.Type: GrantFiled: June 19, 2008Date of Patent: August 30, 2011Assignee: Merck Serono SAInventors: Serge Halazy, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
-
Patent number: 7683078Abstract: The present invention relates to sulfonamide derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are useful in the treatment of neuronal disorders, autoimmune diseases, cancer and cardiovascular diseases. Furthermore, said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and -3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. Formula (I) IAr1 is a substituted or unsubstituted aryl or heteroaryl group; X is O or S, preferably O; Ar2 a substituted or unsubstituted arylene or heteroarylene group; R1 and R2 are independently selected from the group consisting of hydrogen and a C1-C6-alkyl group.Type: GrantFiled: July 15, 2002Date of Patent: March 23, 2010Assignee: Laboratoires Serono S.A.Inventors: Thomas Rueckle, Jean-Pierre Gotteland, Russel J. Thomas, Marco Biamonte
-
Publication number: 20100029719Abstract: The present invention relates to sulfonamide derivatives of formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are useful in the treatment of neuronal disorders, autoimmune diseases, cancer and cardiovascular diseases. Furthermore, said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and -3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation.Type: ApplicationFiled: September 24, 2009Publication date: February 4, 2010Applicant: LABORATOIRES SERONO S.A.Inventors: Thomas RUECKLE, Jean-Pierre Gotteland, Russel J. Thomas, Marco Biamonte
-
Patent number: 7638538Abstract: The present invention is related to sulfonyl amino acid derivatives of formula (I), notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl amino acid derivatives. Said sulfonyl amino acid are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 33. The present invention is furthermore related to novel sulfonyl amino acid derivatives as well as to methods of their preparation.Type: GrantFiled: September 28, 2000Date of Patent: December 29, 2009Assignee: Laboratoires Serono S.A.Inventors: Stephen Arkinstall, Serge Halazy, Dennis Church, Montserrat Camps, Thomas Rueckle, Jean-Pierre Gotteland, Marco Biamonte
-
Patent number: 7544700Abstract: The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble. Said compounds are notably for use as pharmaceutically active compounds. The present invention also related to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation.Type: GrantFiled: September 27, 2001Date of Patent: June 9, 2009Assignee: Laboratoires Serono SAInventors: Serge Halazy, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
-
Publication number: 20090005426Abstract: Sulfonyl hydrazide compounds according to formula I geometrical isomers thereof, optically active enantiomers thereof, diastereomers thereof, racemates thereof, and/or pharmaceutically acceptable salts thereof are useful in method for treating a neuronal disorder, an autoimmune disease, a cardiovascular disease, or cancer in a patient in need of such treatment.Type: ApplicationFiled: July 14, 2008Publication date: January 1, 2009Applicant: LABORATOIRES SERONO S.A.Inventors: Stephen ARKINSTALL, Serge Halazy, Dennis Church, Montserrat Camps, Thomas Rueckle, Jean-Pierre Gotteland, Marco Biamonte
-
Publication number: 20080255222Abstract: The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3.Type: ApplicationFiled: June 19, 2008Publication date: October 16, 2008Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Serge HALAZY, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
-
Patent number: 7432286Abstract: The present invention is related to sulfonyl hydrazide derivatives for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl hydrazide derivatives. Said sulfonyl hydrazide derivatives are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonyl hydrazide derivatives as well as to methods of their preparation.Type: GrantFiled: September 28, 2000Date of Patent: October 7, 2008Assignee: Laboratories Serono SAInventors: Stephen Arkinstall, Serge Halazy, Dennis Church, Montserrat Camps, Thomas Rueckle, Jean-Pierre Gotteland, Marco Biamonte
-
Patent number: 7417058Abstract: The present invention is related to benzsulfonamide derivatives of formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such benzsulfonamide derivatives. Said benzsulfonamide derivatives are ef-ficient modulators of the JNK pathway, they are in particular efficient and selective in-hibitors of JNK 2 and 3. The present invention is furthermore related to novel benzsul-fonamide derivatives as well as to methods of their preparation (I). The compounds of formula I according to the present invention being suitable pharma-ceutical agents are those wherein Ar1 is a substituted or unsubstituted aryl or heteroaryl group. X is O or S, preferably O.R1 is hydrogen or a C1-C6-alkyl group, preferably H.R2 is hydrogen, —COOR3, —CONR3R3?, OH, a C1-C4 alkyl substituted with an OH group, a hydrazido carbonyl group, a sulfate, a sulfonate, an amine or an ammonium salt; n is either 0 or 1, preferably 1.Type: GrantFiled: September 27, 2001Date of Patent: August 26, 2008Assignee: Laboratoires Serono S.A.Inventors: Serge Halazy, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
-
Publication number: 20070185064Abstract: 2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.Type: ApplicationFiled: September 12, 2006Publication date: August 9, 2007Applicant: Conforma Therapeutics CorporationInventors: Srinivas Kasibhatla, Kevin Hong, Marcus Boehm, Marco Biamonte, Lin Zhang
-
Publication number: 20070173483Abstract: Pyrrolopyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Methods of synthesis and use of such compounds are also described and claimed.Type: ApplicationFiled: September 12, 2006Publication date: July 26, 2007Applicant: Conforma Therapeutics CorporationInventors: Srinivas Kasibhatla, Jiandong Shi, Jean-Yves Le Brazidec, Marco Biamonte, Kevin Hong, Marcus Boehm
-
Publication number: 20070129334Abstract: Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same. Methods of using the novel purine compounds of the invention, and tautomers and pharmaceutically acceptable salts thereof, include their use in inhibiting heat shock protein 90's (HSP90's) to thereby treat or prevent HSP90-dependent diseases, e.g., proliferative disorders such as breast cancer.Type: ApplicationFiled: December 18, 2006Publication date: June 7, 2007Applicant: CONFORMA THERAPEUTICS CORPORATIONInventors: Srinivas Kasibhatla, Lin Zhang, Marco Biamonte, Marcus Boehm, Junhua Fan, Jiandong Shi, Kevin Hong
-
Publication number: 20070111996Abstract: Pyrazolopyrimidines and related analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.Type: ApplicationFiled: September 29, 2006Publication date: May 17, 2007Applicant: Conforma Therapeutics CorporationInventors: Srinivas Kasibhatla, Marco Biamonte, Kevin Hong, David Hurst, Marcus Boehm
-
Patent number: 7148228Abstract: A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof: wherein: R1 is halogen, —OR1, —SR11 or lower alkyl; R2 is —NHR8; R3 is selected from the group consisting of hydrogen, halogen, —SR8, —OR8, —CN, —C(O)R9, —CO2H, —NO2, —NR8R10, lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic and heterocyclic, all optionally substituted, wherein: the aryl, heteroaryl, alicyclic and heterocyclic groups are optionally mono-, bi- or tri-cyclic, R4 is —CHR12—, —C(O), —C(S), —S(O)—, or —SO2—; R5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents.Type: GrantFiled: September 20, 2004Date of Patent: December 12, 2006Assignee: Conforma Therapeutics CorporationInventors: Srinivas Rao Kasibhatla, Marco A. Biamonte, Kevin D. Hong, David Hurst, Marcus F. Boehm
-
Patent number: 7138401Abstract: 2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.Type: GrantFiled: September 20, 2004Date of Patent: November 21, 2006Assignee: Conforma Therapeutics CorporationInventors: Srinivas Rao Kasibhatla, Kevin D. Hong, Marcus F. Boehm, Marco A. Biamonte, Lin Zhang
-
Patent number: 7138402Abstract: The present invention provides compounds represented by Formula I.Type: GrantFiled: September 20, 2004Date of Patent: November 21, 2006Assignee: Conforma Therapeutics CorporationInventors: Srinivas R. Kasibhatla, Jiandong Shi, Jean-Yves Le Brazidec, Marco A. Biamonte, Kevin D. Hong, Marcus F. Boehm
-
Publication number: 20060223797Abstract: Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.Type: ApplicationFiled: March 29, 2006Publication date: October 5, 2006Inventors: Srinivas Kasibhatla, Marco Biamonte, Jiandong Shi, Marcus Boehm
-
Publication number: 20050119282Abstract: Pyrazolopyrimidines and related analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.Type: ApplicationFiled: September 20, 2004Publication date: June 2, 2005Inventors: Srinivas Kasibhatla, Marco Biamonte, Kevin Hong, David Hurst, Marcus Boehm